KZIA
NASDAQKazia Therapeutics Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$10.86+2.00 (+22.57%)
2026-03-042026-06-05
News · 26 weeks75+1400%
2025-12-142026-06-07
Mix5090d
- SEC Filings33(66%)
- Insider9(18%)
- Other5(10%)
- Leadership2(4%)
- Analyst1(2%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Davidson Ebru3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- PRThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- PRKazia Therapeutics Appoints James Levine as Chief Financial OfficerSYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies. "James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following an extensive career in investment banking," said Dr.
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- PRKazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast CancerPlanned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability DataSYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced plans to expand its ongoing Phase 1b clinical trial evaluating lead asset paxalisib in combination with standard-of-care therapies in patients with advanced triple negative breast cancer ("TNBC"). Based on continued encouraging safety, tolerability and clinical activity data observed to date, planned enrollment has increased from 12 to
- INSIDERSEC Form 3 filed by new insider Rao Sudha3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 6-K filed by Kazia Therapeutics Limited6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- ANALYSTLaidlaw initiated coverage on Kazia Therapeutics with a new price targetLaidlaw initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $25.00
- PRKazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology PlatformSYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including PD-L1 protein degradation and SETDB1-targeted chromatin modulation. Her appointment brings deep expertise in translational epigenetics, AI-guided epi-drug discovery capability, liquid and spatial epigenetic clinical biomarker precision medicine platforms, and early clinical development
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
- SECSEC Form 424B3 filed by Kazia Therapeutics Limited424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
KZIA FAQ
6 questionsWhat does Kazia Therapeutics Limited do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Where does KZIA stock trade?
Kazia Therapeutics Limited (KZIA) is listed on NASDAQ.What sector and industry is KZIA in?
Kazia Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KZIA?
Kazia Therapeutics Limited has had 3 recent analyst actions on file. The most recent action was from Laidlaw: Buy with a $2500.00 price target on 2026-04-15.What companies are similar to KZIA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KZIA side-by-side with any of them on Quantisnow.How can I track KZIA on Quantisnow?
Quantisnow aggregates Kazia Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KZIA to receive live email and push alerts on every new disclosure.